Anbio Biotechnology Cl A
(NNNN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2025 | 12-2024 | 12-2023 | 12-2022 | |
| Assets | ||||
| Current Assets | ||||
| Cash & Cash Equivalents | 5,349 | 11,761 | 9,688 | 7,102 |
| Marketable Securities | 8,081 | 0 | 0 | 1,567 |
| Receivables | 3,716 | 1,065 | 1,885 | 0 |
| Inventories | N/A | 0 | 0 | 354 |
| Other current assets | 10,173 | 5,708 | 4,177 | 4,920 |
| TOTAL | $27,681 | $18,534 | $15,750 | $13,943 |
| Non-Current Assets | ||||
| Other Non-Current Assets | 0 | 387 | 62 | 3 |
| TOTAL | $N/A | $387 | $62 | $3 |
| Total Assets | $27,681 | $18,922 | $15,812 | $13,958 |
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 60 | 1,625 | 827 | 1,408 |
| Other current liabilities | 71 | 105 | 166 | 3 |
| TOTAL | $131 | $1,730 | $993 | $1,411 |
| Non-Current Liabilities | ||||
| TOTAL | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $131 | $1,730 | $993 | $1,411 |
| Shareholders' Equity | ||||
| Common Shares | 14 | 14 | 14 | 0 |
| Retained earnings | 20,972 | 17,174 | 14,801 | 12,547 |
| TOTAL | $27,550 | $17,192 | $14,819 | $12,547 |
| Total Liabilities And Equity | $27,681 | $18,922 | $15,812 | $13,958 |